Patents by Inventor Wolfgang H. Dillmann

Wolfgang H. Dillmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of calcium binding proteins to improve cardiac contractile function
    Patent number: 8007778
    Abstract: Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow for the identification of agents that modulate sorcin expression. Such agents are useful, for example, for diagnosing cardiac contractile function associated disorders in subjects, and treating the subjects with the agents identified as being able to modulate sorcin expression.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: August 30, 2011
    Assignee: The Regents of the University of California
    Inventors: Wolfgang H. Dillmann, Jorge Suarez, Darrell Belke, Bernd Gloss
  • Gene therapy for myocardial ischemia
    Publication number: 20040132190
    Abstract: The transgene-inserted replication-deficit adenoviral vector is effectively used in in vivo gene therapy for myocardial ischemia in a protective way, by a single intracoronary injection directly conducted deeply in the lumen of the coronary arteries in an amount sufficient for transfecting all cell types in the affected region, including cardiac myocytes.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 8, 2004
    Applicant: The Regents of the University of California
    Inventors: Wolfgang H. Dillmann, Frank J. Giordano, Ruben Mestril
  • Method for in vivo regulation of cardiac muscle contractility
    Publication number: 20030211080
    Abstract: A method for regulating in vivo calcium transport in cardiac muscle of animals suffering from congestive heart failure is disclosed. According to the method, calcium ATPase activity (which decreases as congestive heart failure develops) and cardiac muscle contractility augmented by delivering a gene which operatively encodes the enzyme into the heart. Delivery systems, including but not limited to using adeno-associated viral vectors are provided. Methods for monitoring the expression and effect of the gene product on cardiac performance are also provided.
    Type: Application
    Filed: January 13, 2003
    Publication date: November 13, 2003
    Applicant: The Regents of University of California
    Inventors: Wolfgang H. Dillmann, Frank Giordano, Ruben Mestril
  • Method for in vivo regulation of cardiac muscle contractility
    Patent number: 6605274
    Abstract: A method for regulating in vivo calcium transport in cardiac muscle of animals suffering from congestive heart failure is disclosed. According to the method, calcium ATPase activity (which decreases as congestive heart failure develops) and cardiac muscle contractility augmented by delivering a gene which operatively encodes the enzyme into the heart. Delivery systems (including recombinant expression vectors) are provided, as are methods for monitoring the expression and effect of the gene product on cardiac performance.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: August 12, 2003
    Assignee: The Regents of the University of California
    Inventors: Wolfgang H. Dillmann, Frank Giordano, Ruben Mestril
  • Gene therapies for enhancing cardiac function
    Patent number: 6174871
    Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: January 16, 2001
    Assignee: The Regents of the University of California
    Inventors: H. Kirk Hammond, Frank J. Giordano, Wolfgang H. Dillmann
  • Gene therapies for enhancing cardiac function
    Patent number: 6100242
    Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: August 8, 2000
    Assignee: The Regents of the University of California
    Inventors: H. Kirk Hammond, Frank J. Giordano, Wolfgang H. Dillmann
  • Gene transfer-mediated angiogenesis therapy
    Patent number: 5792453
    Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 11, 1998
    Assignee: The Regents of the University of California
    Inventors: H. Kirk Hammond, Frank J. Giordano, Wolfgang H. Dillmann